NCT05824468View on ClinicalTrials.gov

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions

Cervical CancerCervical Carcinoma

Interventions

DRUG

Zimberelimab

Injectable solution

DRUG

Lenvatinib

Capsule

Trial Locations (1)

510060

Sun Yat-sen University Cancer Cetntre, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER